# Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

> **NCT00195104** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 87 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Arsenic Trioxide (Tricenox)
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00195104
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-17
- **Primary completion:** 2006-03-17
- **Final completion:** 2006-06-20
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195104, "Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00195104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*